Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ACRS Aclaris Therapeutics, Inc. daily Stock Chart
ACRS [NASD]
Aclaris Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.67 Insider Own3.90% Shs Outstand42.13M Perf Week8.92%
Market Cap177.46M Forward P/E- EPS next Y-1.14 Insider Trans0.00% Shs Float38.92M Perf Month81.53%
Income-69.50M PEG- EPS next Q-0.30 Inst Own67.70% Short Float1.78% Perf Quarter94.83%
Sales5.50M P/S32.26 EPS this Y-10.10% Inst Trans-5.14% Short Ratio1.09 Perf Half Y310.91%
Book/sh1.17 P/B3.86 EPS next Y11.60% ROA-91.80% Target Price- Perf Year220.57%
Cash/sh1.73 P/C2.61 EPS next 5Y- ROE-153.90% 52W Range0.70 - 5.04 Perf YTD139.15%
Dividend- P/FCF- EPS past 5Y-57.10% ROI-158.70% 52W High-10.32% Beta1.42
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin18.40% 52W Low545.71% ATR0.37
Employees77 Current Ratio4.00 Sales Q/Q122.20% Oper. Margin- RSI (14)71.33 Volatility7.65% 11.05%
OptionableYes Debt/Eq0.23 EPS Q/Q74.10% Profit Margin- Rel Volume0.73 Prev Close4.51
ShortableYes LT Debt/Eq0.21 Earnings- Payout- Avg Volume633.07K Price4.52
Recom1.20 SMA2034.26% SMA5063.91% SMA200152.37% Volume463,011 Change0.22%
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Oct-20-20 07:00AM  
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical Soft JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
GlobeNewswire
Oct-14-20 10:36PM  
Hedge Funds Are Buying Aclaris Therapeutics, Inc. (ACRS)
Insider Monkey
Oct-01-20 12:00PM  
All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy
Zacks
Sep-30-20 06:40AM  
Could The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Ownership Structure Tell Us Something Useful?
Simply Wall St.
Sep-01-20 04:01PM  
Aclaris Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire -5.28%
Aug-13-20 12:00PM  
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
Zacks
Aug-07-20 08:45AM  
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Zacks +7.69%
07:00AM  
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
GlobeNewswire
Aug-06-20 12:30PM  
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know
Zacks -9.30%
Jul-08-20 08:43AM  
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher
Zacks
Jul-07-20 04:01PM  
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical Soft JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
GlobeNewswire +5.36%
Jun-26-20 02:30PM  
Is Aclaris Therapeutics, Inc. (ACRS) A Good Stock To Buy?
Insider Monkey
Jun-18-20 10:12AM  
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
Zacks
Jun-17-20 10:37AM  
P/E Ratio Insights for Aclaris Therapeutics
Benzinga +16.55%
07:01AM  
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
GlobeNewswire
Jun-03-20 07:00AM  
Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
GlobeNewswire
May-26-20 04:01PM  
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
GlobeNewswire +7.32%
May-12-20 10:47AM  
Will Aclaris Therapeutics Continue to Surge Higher?
Zacks
May-08-20 12:00PM  
All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy
Zacks
May-07-20 04:01PM  
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
GlobeNewswire +8.73%
May-06-20 12:30PM  
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks
Apr-09-20 06:13AM  
Does The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Share Price Fall With The Market?
Simply Wall St.
Apr-06-20 12:00PM  
Aclaris (ACRS) Upgraded to Buy: Here's Why
Zacks
Apr-01-20 11:07AM  
Wayne biopharma firm borrows $11M to fund new business strategy
American City Business Journals
Mar-31-20 04:01PM  
Aclaris Therapeutics Secures $11 Million Term Loan Facility
GlobeNewswire
Mar-17-20 02:46AM  
Edited Transcript of ACRS earnings conference call or presentation 25-Feb-20 10:00pm GMT
Thomson Reuters StreetEvents
Feb-25-20 04:01PM  
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
GlobeNewswire
Feb-24-20 07:31AM  
Is Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Paid At A Competitive Rate?
Simply Wall St.
Feb-19-20 05:00PM  
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
GlobeNewswire
Feb-10-20 07:00AM  
Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
GlobeNewswire
Jan-13-20 05:03PM  
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
Zacks
Jan-10-20 07:13AM  
The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
Benzinga +17.20%
05:40AM  
Some Aclaris Therapeutics (NASDAQ:ACRS) Shareholders Have Taken A Painful 94% Share Price Drop
Simply Wall St.
Jan-09-20 04:27PM  
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
GlobeNewswire
Jan-08-20 08:00AM  
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
GlobeNewswire
Dec-24-19 12:00PM  
Aclaris (ACRS) Upgraded to Buy: Here's Why
Zacks
Dec-12-19 10:33AM  
Did Hedge Funds Drop The Ball On Aclaris Therapeutics, Inc. (ACRS) ?
Insider Monkey
Nov-27-19 03:23PM  
Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)
Business Wire
Nov-21-19 11:39AM  
Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)
Business Wire -11.24%
Nov-18-19 05:34PM  
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
Zacks
Nov-17-19 07:14AM  
Edited Transcript of ACRS earnings conference call or presentation 7-Nov-19 10:00pm GMT
Thomson Reuters StreetEvents
Nov-12-19 04:01PM  
Aclaris Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
Nov-07-19 04:01PM  
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
GlobeNewswire
Oct-31-19 04:01PM  
Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
GlobeNewswire
Oct-29-19 10:33AM  
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks +14.46%
Oct-25-19 07:12AM  
The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug
Benzinga +5.95%
Oct-24-19 04:01PM  
Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
GlobeNewswire
Oct-17-19 09:46AM  
Company News for Oct 17, 2019
Zacks +6.41%
Oct-14-19 10:28AM  
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
Zacks
Oct-11-19 11:46AM  
Wayne biopharma sells rosacea therapy in deal that could bring in $55M
American City Business Journals +19.33%
Oct-10-19 04:02PM  
Aclaris Therapeutics Announces Divestiture of RHOFADE®
GlobeNewswire
Oct-09-19 07:58AM  
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
Benzinga
Oct-08-19 05:01PM  
Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%
GlobeNewswire
01:42PM  
Edited Transcript of ACRS earnings conference call or presentation 8-Aug-19 9:00pm GMT
Thomson Reuters StreetEvents
Oct-07-19 07:25AM  
Does Market Volatility Impact Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Share Price?
Simply Wall St.
Oct-06-19 10:00AM  
Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm
GlobeNewswire
Oct-03-19 07:28AM  
Top Ranked Momentum Stocks to Buy for October 3rd
Zacks
Sep-30-19 12:15PM  
FINAL DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE -9.24%
10:44AM  
FINAL SEPT. 30 DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important Deadline in Securities Class Action ACRS
GlobeNewswire
Sep-28-19 06:30PM  
DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE
10:00AM  
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm
Business Wire
Sep-27-19 08:15PM  
FINAL DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE
03:00PM  
Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire
12:21PM  
Top Ranked Momentum Stocks to Buy for September 27th
Zacks
11:00AM  
DEADLINE ALERT for ACRS, GTT, JE, and NKTR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
GlobeNewswire
10:36AM  
Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action - Bronstein, Gewirtz & Grossman, LLC
ACCESSWIRE
Sep-26-19 04:45PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS
PR Newswire -11.65%
04:45PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS
CNW Group
11:17AM  
Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS
GlobeNewswire
08:19AM  
Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue?
Zacks
Sep-25-19 08:48PM  
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm
PR Newswire +6.83%
03:38PM  
ACLARIS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm
Newsfile
03:15PM  
5-Day Deadline Alert: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE
11:00AM  
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc.
GlobeNewswire
10:35AM  
Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC
ACCESSWIRE
09:00AM  
Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade
Zacks
Sep-24-19 09:10PM  
6-Day Deadline Alert: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE
03:15PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS
GlobeNewswire
03:09PM  
Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS
GlobeNewswire
01:05PM  
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm
Newsfile
Sep-23-19 10:34AM  
Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC
ACCESSWIRE -9.51%
09:35AM  
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
GlobeNewswire
Sep-20-19 03:00PM  
GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire
11:31AM  
GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action ACRS
GlobeNewswire
11:00AM  
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc.
GlobeNewswire
10:44AM  
GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Actions - Bronstein, Gewirtz & Grossman, LLC
ACCESSWIRE
Sep-19-19 07:40PM  
IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE -14.72%
01:30PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS
ACCESSWIRE
11:30AM  
DEADLINE: Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS
ACCESSWIRE
Sep-18-19 07:51PM  
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aclaris Therapeutics, Carbonite, GTT Communications, and Just Energy and Encourages Investors to Contact the Firm
GlobeNewswire -9.44%
05:45PM  
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE
12:23PM  
A Look At Benzinga Pro's Most-Searched Tickers For September 18, 2019
Benzinga
10:42AM  
GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC
ACCESSWIRE
Sep-17-19 08:49PM  
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS
GlobeNewswire +63.64%
02:45PM  
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE
12:29PM  
A Look At Benzinga Pro's Most-Searched Tickers For September 17, 2019
Benzinga
11:15AM  
Why Microcap Biotech Aclaris Is Rallying
Benzinga
07:23AM  
The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study
Benzinga
07:00AM  
Aclaris Therapeutics to Hold R&D Day
GlobeNewswire
Sep-16-19 04:55PM  
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
ACCESSWIRE +6.80%
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
open in yahoo | open in reuters | open in google